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ABSTRACT
Somatic mutations found within the tyrosine kinase domain (TKD) of the human 
epidermal growth factor (HER) family of receptors have been implicated in the 
development and progression of non-small cell lung cancer (NSCLC). However, no 
conclusive reports have described pathogenic mutations in kinase-impaired HER3. 
Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a 
novel HER3V855A somatic mutation homologous to the EGFRL858Ractivating mutation. Co-
expression of HER3V855A and wild-type HER2 enhances ligand-induced transformation 
of murine and human cell lines, while HER-targeted inhibitors potently suppress 
mutant HER3 activity. Consistent with these observations, in silico computational 
modeling predicts that mutant V855A alters the kinase domain and c-terminal end 
of the HER3 protein. Taken together, these findings provide a basis for the clinical 
exploration of targeted therapies in HER3 mutant NSCLC and by extrapolation, in 
other cancers that more frequently carry somatic HER3 mutations.
INTRODUCTION
The identification of activating somatic kinase 
domain mutations in the human epidermal growth factor 
(HER) or the human erythroblastoma virus B (ErbB) 
family of trans-membrane receptors, which consists of the 
four homologous members EGFR (HER1; ErbB1), HER2 
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4), has enabled 
major advancement in the treatment of non-small cell 
lung cancer (NSCLC) [1, 2]. These mutations identified 
in EGFR, HER2 [2] and HER4 [3], cluster around 
their intracellular catalytic tyrosine kinase domain and 
contribute to disease pathogenesis [2, 4, 5]. EGFR kinase 
domain mutations present in approximately 5-10% of all 
NSCLCs [2], highly predict the efficacy of small molecule 
EGFR or pan-HER tyrosine kinase inhibitors (TKIs) with 
response rates as high as 70% seen in multiple randomized 
studies [6-8]. HER2 driver mutations, on the other hand, 
are found in less than 2% of NSCLCs [2]. EGFR and 
HER2 mutation prevalence varies according to patient/
tumor selection criteria. Tumor cells that harbor HER2 
mutations exhibit preclinical and clinical sensitivity to the 
pan-HER inhibitor afatinib [9-11]. The few lung cancer-
derived HER4 kinase mutations reported to date have 
not been extensively studied. HER4 has an attenuating 
role in HER signaling and mutations rather create a loss 
of function [12, 13]. While HER3 mutations have been 
reported in some human cancers [14, 15], no conclusive 
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reports to date have described HER3-related pathogenic 
mutations in lung cancer [16-18]. 
HER3 is unique among the HER receptor family 
members as it is generally considered to lack or have 
impaired tyrosine kinase activity due to the absence of 
critical amino acid residues within its kinase domain 
securing it in an inactive conformation [18-21]. Despite 
this perceived absence of intrinsic tyrosine kinase 
activation, HER3 plays a critical role in the signaling of the 
other HER members. Unlike other HER receptors, HER3 
does not form stable ligand-induced homodimers [22], but 
upon ligand binding acts as an allosteric activator of its 
other HER partners, particularly HER2. This activation 
results in the propagation of a potent signaling cascade 
[18, 20, 23] and can also play a role in carcinogenesis 
[24, 25]. In addition, HER3 contains six binding sites for 
the p85 regulatory subunit of phosphoinositide 3-kinase 
(PI3K) that are not present in EGFR or HER2, establishing 
HER3 as a strong intermediary for PI3K/AKT signaling 
[18, 26].
Here, we report on a novel V855A mutation located 
in exon 21 of the HER3 tyrosine kinase domain and found 
in the tumor specimen of an adolescent patient with a 
chemotherapy-resistant advanced NSCLC. Interestingly, 
this mutation maps at a position homologous to the 
prevalent EGFR-L858R driver mutation [27] and we thus 
hypothesized that this mutant HER3 may have a functional 
impact. We demonstrate that HER3-V855A alters HER3 
protein structure and confers a gain-of-function phenotype 
when co-expressed with HER2 but not with EGFR. We 
also demonstrate that HER-specific therapeutics can 
effectively suppress mutant V855A transforming potential. 
These preclinical results provide a rationale for the clinical 
exploration of anti-HER therapies in HER3 mutant lung 
cancer and by extrapolation in other cancers that more 
frequently harbor HER3 somatic mutations.
RESULTS
Clinical presentation
A 14-year-old Caucasian male presented for 
evaluation with a paresis affecting his left arm. A 
brain MRI demonstrated diffuse multiple lesions with 
uptake of contrast and surrounding edema (Fig. 1c) 
while a subsequent brain biopsy revealed the presence 
Figure 1: A novel HER3 somatic mutation in NSCLC. Clinical findings of a metastatic lung adenocarcinoma in a 14 year old 
male: a. axial computed tomography (CT) image showing primary lesion in left bronchus of patient (arrow), b. H&E stained section of 
transbronchial biopsy specimen showing nests of poorly differentiated adenocarcinoma (arrow) infiltrating the bronchial mucosa (original 
magnification, x20), c. MRI scan of patient showing metastatic brain lesions in the white matter of both the left and right frontal lobes 
(arrows), d. H&E stained section showing metastatic lung adenocarcinoma in brain biopsy. Glial tissue is invaded by nests and sheets of 
tumor cells, growing in a cohesive pattern (arrow) (original magnification, x20) and e. Sanger sequencing chromatograms covering exon 
21 of the HER3 gene revealing a double peak with a novel T-to-C base pair change resulting in a V855A mutation (arrows) in the pleural 
lung biopsy specimen of the patient (right panel). Patient’s peripheral blood specimen (left panel) reveal the wild-type HER3 sequence only.
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of metastasis of an adenocarcinoma (Fig. 1d). The 
immunohistochemical profile of the tumor (CK7 and TTF1 
positive) suggested a primary origin from the lung. Further 
screening via computed tomography (CT) revealed the 
presence of a primary lesion in the left bronchus (Fig. 1a). 
The screening also demonstrated severe metastatic spread 
with multiple thoracic and abdominal adenopathies and 
metastases in the liver and kidneys (data not shown). A 
transbronchial biopsy confirmed the presence of a poorly 
differentiated adenocarcinoma infiltrating the normal 
bronchial tissue, with roughly 40% of the specimen 
consisting of tumor cells (Fig. 1b).
Identification of a novel HER3-V855A mutation
A single arm multicenter phase II clinical study 
initiated in 2006 (FIELT1 study; NCT00339586) was 
coordinated by our department to evaluate the safety and 
efficacy of first-line erlotinib in patients with advanced 
NSCLC with a documented EGFR kinase mutation. 
Patients were pre-selected on the basis of 2 criteria: 
adenocarcinoma with little or no smoking history. Patients 
with an EGFR mutation in their tumor were then treated 
with erlotinib (150mg/day) until progression [28]. DNA 
isolated from formalin-fixed lung cancer biopsy samples, 
including the specimen from the 14 year old male patient, 
were screened for mutations in the kinase domain (exons 
18 through 21) of all four HER family genes by the 
denaturing gradient gel electrophoresis (DGGE) method 
that detects as low as 5% mutant species in a wild-type 
background [29]. Additional screening was also performed 
on exons previously reported to harbor hotspot mutations 
in KRAS and BRAF [2]. From a total of 210 screened 
samples, eighteen previously reported EGFR pathogenic 
mutations (n=55) and two (n=5) previously reported HER2 
insertion mutations were identified [29]. As depicted in 
Fig. 1e, further examination of DNA extracted from 
Figure 2: Protein structure visualization of the novel HER3-V855A mutation. a. Partial amino acid alignment of exon 21 
sequence of the HER3 and EGFR tyrosine kinase domain. Also shown are the positions affected by the EGFR-L858R mutation and the 
novel HER3-V855A mutation (arrows). b. Partial amino acid alignment of the kinase domain of HER3 with other receptor tyrosine kinases 
adapted from the mutagrator kinase mutation interpretation tool reveals mutations (blue) at analogous residues. The HER3-V855A mutation 
is also analogous to the BRAF-L597V kinase mutation (red box). c. 3D structure of HER3 kinase domain (PDB: 3LMG) depicting the 
location of V855A mutation (red van der Waals radii).
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the lung cancer specimen of the 14-year-old case-study 
revealed a double peak at nucleotide c.2564 located in 
exon 21 of the HER3 gene (NM_001982). This indicated 
the presence of a mutated allele with a T-to-C base-pair 
substitution, predicted to substitute valine (GTG) to 
alanine (GCG) at codon 855 (p. Val855Ala; NP_001973) 
of the HER3 activation loop. The HER3-V855A mutation 
was detected in the tumor sample, but was not found in 
the patient’s peripheral blood DNA (Fig. 1e), confirming 
that the mutation was of somatic origin. Additional 
genomic analysis of the patient’s lung tumor specimen 
did not reveal any additional mutations in the other tested 
genes. The disease progressed despite treatment with 
VIDE (vincristin, ifosfamide, doxorubicin and etoposide) 
although there was an initial objective response. 
Unfortunately, demise occurred before the patient could 
be included by amendment in an exploratory lung cancer 
phase II study with afatinib [11].
Homology between the HER3-V855A and EGFR-
L858R kinase mutation
EGFR pathogenic mutations sensitize in varying 
degrees to inhibition by small molecule TKIs [27]. These 
mutations include both class I short in-frame deletions and 
class II missense mutations. One of these mutations, the 
L858R(Leucine → Arginine) missense mutation occurs 
at a highly conserved amino acid among protein kinases 
and is found in exon 21 of the EGFR kinase domain [30]. 
In addition, this single nucleotide substitution has the 
highest prevalence of any activating EGFR kinase domain 
missense mutation, accounting for approximately 41% of 
EGFR kinase mutations [31]. Moreover, EGFR-L858R 
leads to increased sensitivity to EGFR TKIs, albeit with 
less dramatic response than the exon 19 deletion mutation 
[27].
To analyze the location and significance of the 
novel HER3-V855A mutation, we performed protein 
sequence alignment of exon 21 of the EGFR and HER3. 
Although, the amino acid at position 855 in HER3 is not 
conserved relative to EGFR, the mutated amino acid 
remarkably maps at a position analogous to the location 
of the EGFR-L858R mutation (Fig. 2a). Further analysis 
with the Mutagrator kinase mutation interpretation tool 
[32] reveals that the mutated V855 residue also has 
positional homology to the lung cancer-derived BRAF- 
L597V kinase mutation [33] (Fig. 2b). BRAF-L597V 
is classified as an intermediate kinase active variant 
(approximately100 fold elevated BRAF activity compared 
to wild-type) that modestly increases ERK activation [34]. 
The mutated residue is also highly conserved across HER3 
homologs among different mammalian species (data not 
shown), which further indicates that the V855A mutation 
may have a functional effect. In addition, analysis of the 
crystal structure of the HER3 kinase domain depicting 
the mapped location of the mutated residue, demonstrates 
its functional relevance. The V855 residue is part of a 
conserved sequence motif (also includes L858 and L859) 
which stabilizes the inactive position of the αC helix [20]
(Fig. 2c), and we propose that the amino acid substitution 
may likely affect protein kinase activity.
 HER3V855A expressed with HER2WT enhances 
neuregulin1β-induced transformation in a null 
cellular model
HER3 has been described as a contributor to 
oncogenic transformation and tumorigenesis, particularly 
Table 1: IC
50
 values for growth inhibition by HER inhibitors assessed by the MTS colorimetric assay. 
Cell growth was measured following a 7 day drug treatment in the presence of NRG1β. IC
50
 values were calculated by 
the BioSoft ® CalcuSyn 2.0 Software.
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Figure 3: HER3-V855A combined with HER2 enhances neuregulin 1β-induced activity in transformed Ba/F3 cells. 
a. Selected Ba/F3 transfectants were analyzed for cell surface protein expression by staining with HER-specific antibodies to confirm 
recombinant protein expression. HER2 and HER3 co-transfectants were labeled with PE-conjugated anti-HER2 or PE-conjugated anti-
HER3 antibodies. b. Ba/F3 transfectants were cultured for 7 days in the absence or presence of the indicated stimulants. Cell growth was 
analyzed by the MTS assay. c. Ba/F3 co-transfectants were subjected to a methyl cellulose based colony formation assay in the presence of 
the indicated stimulants for 21 days. Magnification, 20X. d. Colonies were quantified using computerized photoshop CS6 analysis. e. Ba/
F3 co-transfectants were cultured in the presence of NRGβ for 5 days. Total cell lysates were analyzed by immunoblot analysis using the 
indicated antibodies. EV, empty vector. Also see supplemental Figure 1 and 2.
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when combined with its HER2 dimerization partner 
[19]. Therefore, we hypothesized that the HER3 kinase 
mutation may cause a pathogenic phenotype when co-
expressed with HER2 in a cellular system. To this end, we 
used the Ba/F3 model system to determine the functional 
impact of HER3-V855A. Ba/F3 cells are dependent on 
interleukin-3 (IL-3) for mitogenesis and lack endogenous 
expression of all the HER receptors (although very 
low HER3 expression has been detected in reverse-
transcriptase polymerase chain reaction (RT-PCR) studies 
[35]), enabling us to focus on the properties of the mutant 
HER3 in a basically null background. Ba/F3 cells were 
co-transfected with vectors encoding differing forms of 
the HER receptors (wild-type HER2, wild-type HER3 or 
mutant HER3). Stable cell populations were screened by 
fluorescence-activated cell sorting (FACS) and selected 
based on matched expression level (within two fold levels) 
of their relevant HER at the cell surface (Fig. 3a). 
To determine the transforming potential of HER3-
V855A in the context of IL-3 -independent growth, Ba/
F3 transfectants were grown in the absence or presence 
of IL-3, or HER cognate ligands (neuregulin1β (NRG1β) 
or transforming growth factor α (TGFα)).NRG1β is a key 
activator of HER3 and its expression by NSCLC cells 
has been described to promote autocrine activation of the 
HER2/HER3 complex [36]. In contrast, TGFα activates 
EGFR and is highly expressed in NSCLC [37]. As shown 
in Fig. 3b, Ba/F3 cells singly expressing wild-type HER3 
or mutant HER3-V855A were unable to grow in IL-3 
free culture conditions, even when supplemented with 
NRG1β or TGFα ligands. On the other hand, while still 
no growth response was observed when co-expressing 
each HER3 construct with wild-type HER2 in absence 
of IL-3, a significantly increased growth response upon 
NRG1β stimulation was observed with the mutant HER3 
combination compared to the wild-type combination (p 
< 0.01). The extent of NRG1β-induced growth in the 
HER3-V855A/HER2 co-transfectant was even greater 
than levels observed in IL-3 treatment conditions (Fig. 
3b). Furthermore, treatment with TGFα did not induce 
a growth response in both wild-type and mutant HER3 
co-transfectants (Fig. 3b), further confirming that the 
presence of a HER3-specific cognate ligand is required to 
promote HER3/HER2 biological activity.
To assess the ability of HER3-V855A to form 
colonies we performed a methyl cellulose-based colony 
formation assay. As shown in Fig 3c & 3d, while NRG1β 
treatment did not induce an increase in colony number 
between the wild-type and mutant HER3 co-transfectants, 
colony size was significantly greater inHER3-V855A 
compared to wild-type HER3 (p < 0.001). The colony 
size upon NRG1β treatment was approximately 25-fold 
greater than under IL-3 treatment with the mutant HER3 
co-transfectant (Fig. 3d). 
We also investigated the functional relevance of 
stable Ba/F3 transfectants co-expressing HER3-V855A 
and EGFR (Supplemental Fig. 1a). While Ba/F3 cells 
co-expressing HER3-V855A and EGFR exerted a robust 
growth response to TGFα treatment (Supplemental Fig. 
1b), they were unable to form colonies with the same 
treatment (Supplemental Fig. 1c). In contrast, Ba/F3 
cells co-expressing wild-type HER3 and EGFR not only 
formed colonies in the presence of TGFα (Supplemental 
Fig. 1c), but also demonstrated equal TGFα-induced 
growth response compared to the mutant HER3-V855A 
combination (Supplemental Fig. 1b). These data suggest 
that the pathogenic effects associated with the HER3-
V855A mutation is not induced by heterodimerization 
with EGFR (upon TGFα stimulation).
We next examined the effect of chronic treatment 
with NRG1β on HER3/HER2 phosphorylation and 
their downstream targets AKT and ERK 1/2 in the Ba/
F3 co-transfectants. As shown in Figure 3e, a five-day 
chronic treatment with NRG1β specifically increased 
levels of phosphorylated HER3 and AKT in HER3-
V855A compared to wild-type HER3. In contrast, while 
chronic NRG1β treatment induced HER2 and ERK1/2 
phosphorylation in HER3-V855A, their levels were 
not enhanced compared to wild-type. Of note, chronic 
treatment with NRG1β neither induced HER3 or HER2 
phosphorylation in Ba/F3 cells expressing HER3-V855A 
combined with a kinase-dead (KD) HER2 isoform 
(Supplemental Fig. 2b). This finding further reveals that 
a competent HER2 receptor is required for mutant V855A 
transforming activity.
HER3V855A enhances neuregulin 1β-induced trans-
phosphorylation of HER2WT
Tyrosine trans-phosphorylation is a major event 
in HER signaling [38]. To examine if HER3-V855A 
enhances trans-phosphorylation of HER2, we performed 
immunoblot analysis on Ba/F3 and HEK 293Tlysates after 
16hr incubation in serum-free conditions followed by10 
minute acute ligand stimulation. HER3-V855A enhanced 
trans-phosphorylation of HER2 at Y1248 in both Ba/F3 
and HEK 293T cells after NRG1β stimulation (Fig. 4a and 
4b). 
In addition, while acute treatment with NRG1β 
was essential for the induction of HER3 phosphorylation 
in wild-type and mutant HER3 co-transfectants, HER3 
phosphorylation was absent in similar treatment conditions 
with corresponding single transfectants (Fig. 4a and 
supplemental Fig. 3a). NRG1β-induced phosphorylation 
of mutant HER3 was strongly enhanced in HEK 293T 
cells, whereas the observed effect in Ba/F3 transfectants 
was more modest (Fig. 4a and 4b). Likewise, a modest 
increase in ligand-induced phosphorylation of HER2 
and HER3 was observed in transformed H292 cells 
(Supplemental Fig 3b). H292 cells are NSCLC cells that 
display similar mucoepidermoid features as normal lung 
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(non-cancerous) cells. Consistent with previous functional 
experiments (see Fig. 3), TGFα was unable to induce HER 
phosphorylation in transformed Ba/F3 cells (Fig. 4a). 
Enhanced interaction of HER2 with HER3V855A
To further confirm that the V855A mutation 
provides increased activity to HER3 through enhanced 
physical interaction with HER2, we performed co-
immunoprecipitaton experiments on Ba/F3 co-
transfectants stimulated with or without NRG1β (10 
minutes) after 1 hr serum starvation. Pull down of 
HER3 on HER2 immunoprecipitates revealed enhanced 
interaction of HER2 with HER3-V855A relative to wild-
type HER3, specifically after incubation with NRG1β 
(Fig 5a). Interestingly, reciprocal analysis with HER3 
immunoprecipitates demonstrates that HER2 already 
interacts with the mutant HER3 complex in the absence of 
NRG1β (with no observed effects with ligand stimulation), 
while NRG1β stimulation is needed for interaction with 
the wild-type HER3 protein (Fig. 5b). Of note, the cell 
surface protein expression of HER2 is much higher than 
HER3 in the transfected Ba/F3 cells (Fig. 3a). This thus 
infers that a smaller fraction of the HER3 complex is 
pulled down in Fig. 5b, and may also result in differences 
in the amount of proteins stimulated by NRG1β.
Efficacy of HER inhibitors on transforming 
activity of HER3V855A
To investigate whether HER3-V855A can be 
therapeutically targeted; we examined the growth 
inhibitory effects of inhibitors targeting the extracellular 
and kinase domain of the HER receptors. These 
Figure 4: HER3-V855A enhances neuregulin 1β-induced activation of HER2 in transformed cells. a., b. Western blot 
analysis of Ba/F3 and HEK 293T transfectants treated for 16hrs in serum free conditions (SFM) and stimulated for 10 minutes with the 
indicated EGFR/HER cognate ligands. The cells were subsequently lysed and subjected to immunoblot analyses. Also see supplemental 
Figure 3.
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inhibitors include: erlotinib, an FDA approved reversible 
TKI indicated for the treatment of advanced NSCLC 
and pancreatic cancer, afatinib, a second generation 
irreversible ErbB family blocker also approved for 
the treatment of advanced NSCLC and pertuzumab, a 
monoclonal antibody that targets the extracellular region 
of HER2 preventing it from dimerizing with its other HER 
partners and approved for the treatment of HER2 amplified 
breast cancer in combination with trastuzumab [39-41]. 
To assess the inhibitory effect of these molecules on cell 
growth, Ba/F3 transfectants growing in NRG1β containing 
medium were treated with increasing concentrations of 
these inhibitors for a period of seven days. Afatinib and 
pertuzumab each demonstrated high efficacy in inhibiting 
the growth of Ba/F3 cells co-expressing HER3-V855A 
and wild-type HER2 (Fig. 6a), with IC
50
 values of < 1 
nmol/L and < 1μg/mL respectively (Table 1). Erlotinib, 
on the other hand, had a much weaker inhibitory effect on 
the mutant V855A combination (Fig. 6a) with a calculated 
IC
50
 value of 344±4nmol/L (Table 1). Ba/F3 cells co-
expressing wild-type forms of HER3 and HER2 were 
highly resistant to erlotinib treatment (7000±106 nmol/L), 
but displayed sensitivity to afatinib with an IC
50
 value of 
208 ± 39nmol/L, two logs less sensitive than the mutant 
form (Table 1).
To assess the effect of the inhibitors on colony 
formation, Ba/F3 co-transfectants were seeded onto 
methyl-cellulose and treated with HER inhibitors in 
the presence of NRG1β. As shown in Fig 6b, afatinib 
(100 nmol/L) and pertuzumab (5µg/mL) were effective 
in suppressing the formation of colonies in wild-type 
HER3 and mutant V855A co-transfectants. As expected, 
erlotinib (100nmol/L) was less effective than the other 
HER inhibitors in suppressing colony formation. The 
HER3-V855A co-transfectantformed significantly smaller 
colonies (7.2 ± 1.4) compared to the wild-type HER3 
combination (78.9 ± 13.7) under erlotinib treatment (Fig. 
5b and 5c).
We further examined the effects of the inhibitors 
on HER-related signaling activity and survival using 
the Ba/F3 model system. Afatinib (100nmol/L) potently 
inhibited NRG1β-induced phosphorylation of HER3, wild 
type HER2 and AKT (Fig. 6d). Pertuzumab (5 µg/mL) 
treatment induced less potent effects compared to afatinib, 
with significant reduction seen in mutant HER3 and wild-
type HER2 phosphorylation, but not in active levels of 
AKT (Fig. 5d). Treatment with erlotinib (100nmol/L) 
also inhibited the HER pathway, albeit less potently than 
afatinib or pertuzumab treatment (Fig. 6d). As determined 
by the annexin-V/7-AAD binding assay, treatment with 
afatinib in the presence of NRG1β induced a two-fold 
higher fraction of apoptotic cells compared to vehicle 
conditions (30.3 ± 0.6%). Erlotinib and pertuzumab were 
less effective, yielding respectively a 20.4 ± 0.29% and 
13.9±0.6% increase in apoptotic cells compared to vehicle 
(Fig. 5e). All tested inhibitors were also less effective in 
suppressing HER-related activity and survival in the 
wild-type HER3/HER2 co-transfectant (Fig. 5d and 5e), 
indicating that tumors harboring HER3-V855A may 
predict response to targeted therapy.
Impact of V855A on HER3 protein structure 
To elucidate and predict the impact of mutant V855A 
on the conformation of the wild-type HER3, protein 
modeling was performed via the automated I-TASSER 
server [42]. Server predicted models were further refined 
by submitting the PDB files to Mode Refiner server 
[43]. Ultimately moderefined predicted models were 
Figure 5: Enhanced interaction of HER2 with HER3-V855A Ba/F3 transfectants co-expressing HER2 and HER3 were 
treated in serum free conditions (SFM) for 1 hr followed by a 10-minute stimulation with NRG1β. Total cell lysates were 
co-immunoprecipitated with either HER2 or HER3 antibodies, followed by western blot analysis. 20% input levels are indicated.
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Figure 6: Effectiveness of HER inhibitors on biological activity of HER3-V855A in transformed Ba/F3 cells. a. Dose-
dependent growth inhibition of Ba/F3 co-transfectants treated with the indicated inhibitors and grown in the presence of NRG1β for 7 
days. Cell growth was assessed by the MTS assay. b. Ba/F3 co-transfectants were subjected to a methyl cellulose based colony formation 
assay in the presence of NRG1β and treated with the indicated inhibitors or vehicle control (0.01% DMSO) for 21 days. c. Colonies were 
quantified using computerized photoshop CS6 analysis. Magnification , 20X (Mann Whitney U test: ***,p< 0.001. d. Following overnight 
serum starvation, Ba/F3 co-transfectants were treated with the indicated inhibitors or vehicle control (0.01% DMSO) for 2 hours and then 
stimulated with 100ng/mL of NRG1β for 10 minutes. Immunoblot analysis was performed with the indicated antibodies. e. Ba/F3 co-
transfectants treated with the indicated inhibitors (erlotinib (1µM), afatinib (1µM) and pertuzumab (20 µg/mL)) or vehicle control (0.1% 
DMSO) were grown in the presence of NRG1β for 5 days and evaluated by the Annexin V-APC/7-AADbinding assay. f. Quantification 
of apoptosis with the sum of early and late apoptotic cell populations (only Annexin V stained) in the y-axis plot.Results are the averages 
from two replicate studies. Also see Table 1.
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superimposed on alpha-carbon to unravel structural 
differences. In addition, we compared moderefined 
predicted wild-type HER3 with the crystallography 
obtained model of the HER3 kinase domain (PDB: 
3LMG). Although server predicted wild type HER3, 
differed from the crystallography obtained model, 
comparison of the predicted wild-type and mutated models 
showed significant structural differences (data not shown).
Superimposition of predicted wild-type / mutated HER3 
protein models [44] reveals that the V855A mutation alters 
the kinase domain and the carboxyl-terminal end of the 
wild-type HER3 protein as shown by the blue bars along 
the prediction track depicted in Figure 7.
Taken together, these data suggest that the V855A 
mutation alters the activity of HER3, which may correlate 
with a malignant phenotype.
Figure 7: Prediction track depicting the impact of V855A on HER3 protein structure. a. SNPs from dbSNP (http://www.
ncbi.nlm.nih.gov/SNP) were plotted with synonymous, non-synonymous and non-validated SNPs in green, red and gray respectively. b. 
Alignment generated conservation track shows the extracellular region (residues 20-643) in light green, the kinase domain (709-966) in red 
and the regulatory carboxyl-terminal end (967 - 1342) in gray. The cysteine rich furine-like repeats have been marked with numbers (1-5) 
along the track. The position of the valine to alanine substitution has been marked with an M. c. Server predicted wild-type and mutated 
models were energy minimized, refined and compared in means of  root-mean-square deviation (RMSD) using a derivative of genetic 




We report a unique case of an adolescent patient with 
advanced adenocarcinoma of the lung harboring aHER3-
V855A kinase mutation in his tumor specimen. Although 
HER3 mutations have been identified and characterized 
in colon and gastric cancers [45], no published studies to 
our knowledge have reported the occurrence of clinically 
relevant lung cancer-derived mutations. In addition, we 
present evidence that the HER3-V855A mutation confers 
a gain-of-function phenotype and is highly sensitive 
to HER inhibitors afatinib and pertuzumab. No other 
examined mutations (EGFR, HER2, HER4, KRAS or 
BRAF) were found in the lung tumor specimen of the 
patient, suggesting that HER3-V855Ais the primary driver 
for the lung cancer pathogenesis. Our data also strongly 
suggests that the poor therapeutic response to combination 
chemotherapy could have been circumvented by molecular 
targeted therapy. In addition, this mutation is rare as it 
was found once in a systematic screen of 210 lung cancer 
specimens phenotypically enriched for adenocarcinoma in 
patients with non- or limited smoking history.
The V855A mutation targets the activation loop of 
the HER3 gene and is homologous to the EGFR-L858R 
mutation. Amino acid substitutions that have an impact 
on the biophysical or structural properties of a protein 
have been described to be pathogenic or deleterious [46]. 
We demonstrate with protein modeling that the valine to 
alanine substitution at position 855 has an impact on the 
kinase domain and carboxyl-terminal end of the wild-type 
HER3 protein. Based on this in silico approach, mutant 
V855A may thus confer a pathogenic phenotype by 
destabilizing wild-type HER3. 
As demonstrated by prior studies [47] and confirmed 
by us, the EGFR-L858R mutation is able to transform Ba/
F3 cells to IL-3 independent growth and constitutively 
enhances EGFR autophosphorylation as a homodimer. 
However, HER3-V855A is unable to transform Ba/
F3 cells to either IL-3 independent or ligand-induced 
growth as a homodimer. Rather, it must associate with its 
preferred dimerization partner, HER2, upon binding of an 
exogenous substrate such as NRG1β in order to transform 
Ba/F3 cells. Multiple lines of evidence support this 
finding, demonstrating that the wild-type HER3 receptor’s 
impaired kinase activity can be circumvented by ligand-
induced heterodimerization; preferably with its HER2 
partner [19, 23]. Jaiswal et al. also demonstrated that the 
major colon/gastric cancer-derived HER3 mutants depend 
on HER2 for their oncogenic activity, but in contrast to our 
findings these mutants promote transformation in a ligand-
independent manner [45].
The transforming potential of HER3-V855A 
compared to wild-type HER3 was confirmed by its ability 
to increase ligand-induced coupling of signal transducers 
that mediate proliferative and pro-survival responses, 
indicating a gain-of-function phenotype. Functional data 
from our cellular models demonstrate that HER3-V855A 
strongly enhances NRG1β-induced trans-activation of 
HER2 compared to wild-type HER3. Enhanced trans-
activation of HER receptor activity appears to be a central 
event in receptor tyrosine kinase (RTK) activation by lung-
cancer derived EGFR/HER mutations [36]. This activation 
nonetheless requires a competent HER2 kinase, as our 
data also reveal that HER3-V855A is unable to induce 
trans-activation of kinase-dead HER2. This finding thus 
indicates that HER3 phosphorylation in cells expressing 
mutant V855A requires the catalytic activity of HER2.
A recent study by Littlefield and colleauges has 
demonstrated that cancer-associated HER3 variants may 
not increase the catalytic activity of HER3, but may 
possibly increase the allosteric activator function and 
interaction of HER3 to its dimerization partner [48]. 
Our co-immunoprecipitaton experiments support these 
findings, where we demonstrate enhanced interaction 
between the wild-type HER2 protein complex and 
mutant HER3. This enhanced interaction between the two 
dimerization partners can consequently lead to increased 
activation, alterations of the angle of the ATP binding 
cleft and a more pronounced sensitivity to tyrosine kinase 
inhibitors [49]. 
On the other hand, HER3-V855A combined with 
EGFR does not enhance ligand-induced transformation 
of Ba/F3 cells. Whereas wild-type HER3 combined 
with EGFR is able to form colonies under chronic TGFα 
treatment, the mutant HER3-V855A combination does 
not. Our findings thus demonstrate that mutant V855A can 
be delineated into two distinct phenotypes, depending on 
which HER receptor it associates with. The mechanism, 
however, behind these differing effects is currently 
unknown. [48]. Some theoretical possibilities could be due 
to (1) phosphotransferase activity occurring either through 
a dissociative (inactivating) or associative (activating) 
state [50] when mutant V855A is coupled with EGFR or 
HER2 respectively, or (2) a weaker ligand-induced trans-
phosporylation of HER3 by EGFR. In line with this, Shi 
et al. present data showing that HER3-V855A on its own 
reduces mant [2′-(3′)-O-(N-methylanthraniloyl)] -ATP 
binding compared to the wild-type HER3 protein [20].
While the observations of Shi et al. implicate mutant 
V855A as a suppressor of HER3 kinase activity, further 
work is needed to establish its capacity to bind ATP when 
influenced by its relevant HER dimerization partner. 
Our analysis also shows that inhibitors targeting 
the extracellular and kinase domain of the HER receptors 
are effective in suppressing HER3-V855Adriven activity, 
albeit with differing potency. As expected, afatinib was 
more effective than erlotinib in suppressing growth and 
survival signals due to its target specificity and ability to 
irreversibly bind to the HER kinase. It should be noted, 
however, that HER3 lacks a conserved cysteine group 
found in the kinase domain of the other HER family 
members that is essential for effective binding of afatinib 
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[9]. Afatinib is thus able to exert its potency by inhibiting 
the trans-activation of HER2 by HER3. Pertuzumab, 
an inhibitor targeting HER2 dimerization, was also 
effective in suppressing the transforming potential of 
mutant V855A; further indicating that coupling with 
HER2 is essential for its oncogenic activity. Conversely, 
trastuzumab (an inhibitor targeting the HER2 extracellular 
domain), is ineffective in blocking mutant V855A activity 
(unpublished data not included in this report). Previous 
studies have shown that while pertuzumab efficiently 
blocks ligand-induced HER3/HER2 heterodimerization 
[51], trastuzumab is more effective in blocking ligand-
independent HER3/HER2 interactions [52]. These findings 
are consistent with results presented by the research group 
of Jaiswal in the framework of ligand-independent mutant 
HER3 [45]. All tested inhibitors exhibited less potent 
effects of transformed Ba/F3 cells expressing wild-type 
HER3 combined with HER2 upon NRG1β stimulation. 
This provides a strong biological rationale in establishing 
mutant V855A as a predictive marker in the context of 
response to HER targeted therapy. Accordingly, our 
results will also be useful in evaluating targeted treatment 
approaches in ongoing clinical trials for patients with 
mutant HER3 NSCLC (CTBE2013000234; HER3-
LungNCT02134015).
In conclusion, the identification of HER3-V855A 
and its functional properties for the first time clearly 
implicates genomic HER3 activation in the pathogenesis 
of lung cancer. HER3 is traditionally referred to as a 
kinase-dead or kinase-impaired HER family member 
due to evolutionary divergence at critical residues within 
its kinase domain [18]. The capacity of a single amino 
acid substitution in the HER3 kinase to enhance trans-
activation of HER2 opens up the possibility that other 
regulatory mechanisms can be involved in its catalytic 
function. Our findings thus establish the HER3 kinase 
as a target for cancer therapy and support its continued 
assessment and validation as a potential therapeutic 
modality for personalized-tailored cancer treatment.
MATERIALS AND METHODS
Study population
Patients (n= 210) were prospectively enrolled 
between May 2006 and March 2010 in an academic 
single-arm multicenter phase II study in Belgium and 
Luxemburg (FIELT study; NCT00339586). The study was 
approved by the institutional and ethics review board of 
each participating center. Histologically or cytologically 
confirmed locally advanced or metastatic (Stage IIIb or 
Stage IV) adenocarcinoma of the lung, and a non- to 
poor smoking history were the key eligibility criteria for 
the study. Patients with insufficient tumor material for 
genetic testing or results classified as inconclusive due to 
a low amount of malignant cells in tumor specimen were 
excluded from the analysis (n=65).All patients provided 
separate written informed consent for genetic analysis of 
their tumor specimens and subsequent inclusion in the 
treatment phase of the study.
Mutational screening 
Mutation analysis was performed on DNA extracted 
from three consecutive 10µm thick sections of formalin 
fixed and paraffin embedded tissue. Tissue sections 
were examined to verify the presence of a sufficient 
amount of malignant cells and manually macro-dissected 
when necessary. Tissue area ranged from 1 mm2 to 600 
mm2, although 40% of the sections were smaller than 5 
mm2 (mostly needle biopsies). The mutation screening 
assay at that time (2006) was based on the polymerase 
chain reaction (PCR)-derived denaturing gradient gel 
electrophoresis (DGGE) method that covered the genomic 
regions that encode the tyrosine kinase domain (exons 18-
21) of all 4 HER family genes. DGGE is a very sensitive 
method that can detect mutant DNA species based on 
the differential melting properties of homoduplex and 
heteroduplex PCR fragments with abnormally migrating 
bands revealing the presence of a genomic variant[29, 
53, 54]. Samples were also analyzed for the presence of 
somatic mutations of BRAF (exons 11 and 15) and KRAS 
(exon 2).Mutations were confirmed by Sanger dideoxy-
terminator sequencing according to established methods.
DNA constructs and site-directed mutagenesis
The pcDNA3.1 HER3 hygro (+) expression plasmid 
kindly provided by Dr. M. Rødland (Espen Stang Institute 
of Pathology, Oslo Norway) was constructed as previously 
described [47, 55]. Likewise, the pErbB3-eCFP expression 
vector was provided by Dr. Rong-Hua Tao (Okinawa 
Institute of Science and Technology, Okinawa Japan) and 
was constructed as described [56]. To construct pHER2-
FLAG-CMV-14, a fragment encoding the full length 
sequence of HER2 with a Hind III site at the N terminus 
and Xba I site at the C terminus was PCR amplified. 
The resulting PCR fragment was digested with Hind III 
and Xba I and subsequently cloned into the p3xFLAG-
CMV-14 vector. pcDNA 3.1 neo (+) expressing full length 
HER2 or HER2-K753M (kinase-dead) was constructed 
as previously described [57]. pcDNA3.1hygro (+) was 
purchased from Invitrogen and pcDNA3HER2 neo (+) 
was obtained from Addgene Inc. The HER3-V855A 
mutation was generated by the Gene TailorTM Site-
Directed Mutagenesis kit (Invitrogen) following the 
manufacturer’s instructions with modifications. Mutagenic 
oligonucleotides were designed using standard primer 
design procedures and synthesized by Eurogentec. All 
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mutated constructs were verified by restriction- digestion 
and sequencing analysis. Primer sequences are available 
upon request.
Cell culture
Ba/F3 cells kindly provided by Dr. J. Jiang (Dana-
Farber Cancer Institute), were maintained in RPMI 1640 
(Gibco, Belgium) supplemented with 10% fetal bovine 
serum, 10 units/mL penicillin, 10 µg/mL streptomycin 
and interleukin-3 (Sigma) at 10ng/mL. To generate 
stable polyclonal cell populations, Ba/F3 cells were 
electroporated at 220V/1500mF (SEDD electropore 
2000) with 20µg of a single expression vector or 10µg 
each for paired combinations. Each of the expression 
vectors was linearized with restriction endonucleases 
before transfection. Transfected cells were selected in the 
presence of 1200µg/mL G418 or 1200 µg/mL hygromycin 
for single transfections or 1000µg/mL G418 + 1000µg/mL 
hygromycin for co-transfections. Stable polyclonal cell 
lines were selected by fluorescence-activated cell sorting 
analysis using EGFR, HER2 (BD Biosciences) and HER3 
(R&D systems) specific antibodies and cultured for further 
study.HEK 293T cells (American Type Culture Collection) 
were maintained in DMEM supplemented with 10% 
fetal bovine serum, 10 units/mL penicillin and 10μg/mL 
streptomycin. NCI-H292 cells (American Type Culture 
Collection) were maintained in RPMI 1640containing10% 
fetal bovine serum, 10 units/mL penicillin and 10μg/
mL streptomycin. Transient transfection was performed 
with Lipofectamine2000 (Invitrogen) according to the 
manufacturer’s instructions.
Inhibitors
The reversible HER-specific TKI erlotinib 
(Tarceva®) and HER2-specific monoclonal antibody, 
pertuzumab (Perjeta®) were provided by Roche. The pan-
HER/ErbB TKI afatinib (BIBW 2992) was provided by 
Boehringer Ingelheim. Stock solutions of erlotinib and 
afatinib were prepared at a concentration of 10 mmol/L 
in dimethyl sulfoxide (DMSO) and stored at −80°C. 
The drugs were diluted to a working concentration of 
1mmol/L in DMSO before each experiment with a final 
concentration of 0.1% DMSO used in all experiments.
Growth assays
Cell growth was assessed by the colorimetric 
tetrazolium MTS assay (Promega). Ba/F3 transfectants, 
cells were seeded in clear-bottomed 96-well plates at a 
density of 1x104cells/ well in triplicates or quadruplets. 
Growth factor studies were performed by stimulating 
cells with 100ng/mL of HER cognate ligands [EGF (Cell 
signaling Technology), TGFα and neuregulin-1β (Abcam)]. 
For drug inhibition studies, the cells were pre-treated 
with various concentrations of the indicated drugs and 
subsequently stimulated with 100ng/mL of the indicated 
HER cognate ligands. After 7 days, the numbers of viable 
cells were analyzed at an absorbance of 490nm using 
a96-well microplate reader (Labsystems) according to the 
manufacturer’s instructions. All drug treatment conditions 
were compared to the vehicle control. IC
50
 values were 
assessed by the Biosoft® CalcuSyn version 2.0 software 
(Biosoft).
HER tyrosine phosphorylation, immunoprecipitation, 
and Western blot
To analyze tyrosine phosphorylationof HER 
proteins, Ba/F3 transfectants were incubated at 37oC for 
16 hours in serum free conditions to obtain basal tyrosine 
phosphorylation. Aliquots containing 4x106 cells were 
stimulated with their indicated HER cognate ligand 
for 10 min and lysed in a Tris-buffer [25 mmol/L Tris-
HCL (pH 7.4), 150 mmol/L NaCl, 1% Triton-x, 5ug/
mL leupeptin]containing a protease and phosphatase 
inhibitor cocktail (Sigma). Lysates were cleared by 
centrifugation and protein concentration was determined 
by the Bradford protein assay kit (Bio-Rad) and equivalent 
amount of protein were loaded on a 7.5% resolving 
acrylamide gel and blotted on a polyvinyliden fluoride 
membrane (PVDF). The membrane was then subjected 
to an immunodetection procedure using the indicated 
antibodies:phospho-HER2 (Tyr 1248), phospho-HER3 
(Tyr 1289), HER2, HER3 and AKT/PKB from Cell 
Signaling, phospho-AKT⁄PKB (Ser 473) from Invitrogen, 
and β-actin from Sigma-Aldrich. Horseradish peroxidase 
(HRP)-conjugated secondary antibodies (GE Healthcare; 
Cell Signaling) and a chemoluminescent detection kit 
(Perkin-Elmer) were used to detect the indicated proteins. 
To assess the inhibition of HER tyrosine phosphorylation 
and their downstream targets, Ba/F3 transfectants were 
incubated at 37oC for 16 hours in serum free conditions. 
The cells were then incubated for 2 hours at 37oC with 
required inhibitors followed by10 minute stimulation 
with NRG1β. Cells were subsequently collected and 
used for Western blot analysis as described. To assess the 
protein-protein interaction between HER3 and HER2, Ba/
F3 transfectants were stimulated for 10 minutes with or 
without 100ng/ml NRG1β after one hour incubation in 
serum free conditions and precipitated with the 5μg of 
the indicated antibodies and 75μl of G Sepharose beads 
(GE healthcare). The precipitates were eluted with SDS 




Stable Ba/F3 transfectants (1x105) were suspended 
in 0.5% methylcellulose solution (Sigma) containing the 
required stimulants or inhibitors. Cell suspensions were 
plated on to 6 well plates, incubated for 21 days and 
assessed for colony formation. The mean colony size for 
each condition was determined by means of computerized 
Photoshop CS6 analysis.
Annexin V/7-AAD assay
Cellular apoptosis was determined by the Annexin 
V-APC and 7-Amino-actinomycin D (7-AAD) binding 
assay (BD Biosciences). Briefly, inhibitor treated (erlotinib 
(1µM), afatinib (1µM) and pertuzumab (20 µg/mL)) Ba/
F3 co-transfectants were seeded at a concentration of 
approximately 1 x 106 cells/mL and collected after 5 days. 
The cells were stained according to the manufactures 
instructions and analyzed by fluorescence-activated cell 
sorting (Becton Dickinson). The percentage of early and 
late apoptotic cells were calculated using FlowJo version 
7.5.2 software (TreeStar). 
Protein crystallography
The X-ray crystallographic structure representing 
the inactive state of the HER3 kinase domain (PDB: 
3LMG) was analyzed using Deepview-Swiss-PDB viewer 
v4.1.0 [58] and POV-RAY v3.6 [59] bioinformatics tools. 
Protein modeling and prediction
Predicted models were generated by submitting raw 
wild-type (Protein: NP_001973.2, cdna: NM_001982.3) 
and mutated HER3 p.V855A fasta sequences to the 
automated I-TASSER server [42]. Generated models were 
then energy minimized via two cycles of steepest descent 
consisting of 50 steps each and one cycle of conjugate 
gradient consisting of 200 steps with a minimum ΔE 
of 0.01kJ/mol together with a harmonic constraint of 
100 kJ/mol. Models were also refined using Modrefiner 
[43]. Models were compared to each other and to crystal 
structures of HER3 kinase domain (PDB: 3LMG) and 
extracellular domain (PDB: 1M6B) by X-ray diffraction. 
Server predicted models were compared to each other 
by RMSD difference. Conservation data were generated 
by alignment between Homo sapiens, Mus musculus, 
Rattus norvegicus and Pongo abelii. All renderings and 
modifications were performed using bioinformatics tools 
as described [58, 59].
Statistical Analysis
Results are representative of three independent 
experiments unless stated otherwise. Values are presented 
as the mean ± standard error of mean (SEM). The unpaired 
two-tailed t-test was utilized to compare the means of two 
groups while the Mann Whitney U test was utilized when 
comparing colony size in the colony formation assay. 
Statistical significance is reported as follows:*, P < 0.05, 
**, P < 0.01 and ***, P < 0.001.
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